BioTrove Completes a $15 Million Financing Round
News Mar 09, 2006
BioTrove, Inc. has announced that the company has completed its latest fundraising by closing an additional $7 million in an oversubscribed round of venture capital funding.
The proceeds of this round will accelerate the commercialization of BioTrove's OpenArray™ genomics and RapidFire™ pharmaceutical screening products.
"The investment syndicate's outstanding level of commitment reflects the progress BioTrove has made in commercializing its OpenArray™ and RapidFire™ technologies," said Joshua Phillips, Managing Director at Catalyst Health and Technology Partners and a member of BioTrove's Board of Directors.
"The rapid acceptance of BioTrove's first products based on these technologies proves the tremendous value of the platforms. We are pleased to help the company continue its rapid growth."
Robert H. Ellis, Chairman, President, and CEO of BioTrove noted, "This fundraising signifies a strong endorsement of the technology and our business strategy."
"We have had good initial market acceptance of our OpenArray™ SNP Genotyping product, and we will use the new funds to expand our OpenArray™ platform commercialization efforts."
Dr. Enrico Petrillo, General Partner of CB Health Ventures, LLC, said, "BioTrove's development of the OpenArray™ plate, based on nanofluidics, represents a technology breakthrough for the genetics research and applied genomic markets."
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Hay Fever Risk Genes Overlap with Autoimmune DiseaseNews
In a large international study involving almost 900,000 participants, researchers from the University of Copenhagen and COPSAC have found new risk genes for hay fever. It is the largest genetic study so far on this type of allergy, which affects millions of people around the world.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019